LogicBio Therapeutics Inc
NASDAQ:LOGC
Intrinsic Value
LogicBio Therapeutics, Inc. engages in the development of genome editing technology platform. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of LOGC.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of LogicBio Therapeutics Inc's business.
What risks and challenges
does LogicBio Therapeutics Inc face in the near future?
Summarize the latest earnings report
of LogicBio Therapeutics Inc.
Provide P/E
for LogicBio Therapeutics Inc and its competitors.
Balance Sheet Decomposition
LogicBio Therapeutics Inc
Current Assets | 32.8m |
Cash & Short-Term Investments | 30.8m |
Other Current Assets | 2m |
Non-Current Assets | 5.8m |
PP&E | 5.2m |
Other Non-Current Assets | 622k |
Current Liabilities | 16.4m |
Accounts Payable | 1.1m |
Accrued Liabilities | 3.7m |
Other Current Liabilities | 11.7m |
Non-Current Liabilities | 6.4m |
Long-Term Debt | 2.6m |
Other Non-Current Liabilities | 3.8m |
Earnings Waterfall
LogicBio Therapeutics Inc
Revenue
|
10.8m
USD
|
Operating Expenses
|
-36.6m
USD
|
Operating Income
|
-25.9m
USD
|
Other Expenses
|
-654k
USD
|
Net Income
|
-26.5m
USD
|
Free Cash Flow Analysis
LogicBio Therapeutics Inc
What is Free Cash Flow?
LOGC Profitability Score
Profitability Due Diligence
LogicBio Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
LogicBio Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
LOGC Solvency Score
Solvency Due Diligence
LogicBio Therapeutics Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
LogicBio Therapeutics Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LOGC Price Targets Summary
LogicBio Therapeutics Inc
Ownership
LOGC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
LOGC Price
LogicBio Therapeutics Inc
Average Annual Return | -7.02% |
Standard Deviation of Annual Returns | 24.28% |
Max Drawdown | -98% |
Market Capitalization | 68.2m USD |
Shares Outstanding | 32 962 700 |
Percentage of Shares Shorted | 1.17% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
LogicBio Therapeutics, Inc. engages in the development of genome editing technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2018-10-19. The company is focused on genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. Its genome editing platform, GeneRide, is an approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid repair process, potentially to durable therapeutic protein expression levels. Its gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate, LB-001 is developed for the treatment of methylmalonic acidemia (MMA) in pediatric patients. LB-001 is designed to introduce a functional copy of the methylmalonyl-CoA mutase (MUT) gene into the genome of MMA patients. The company is developing LB-401 for the treatment of hereditary tyrosinemia type 1. The company is also developing LB-301 for the treatment of Crigler-Najjar syndrome (CN).